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The Human Lung Mast Cell
by Stephen 1. Wasserman*
Mast cells are present in human lungtissue, pulmonary epithelium, and free in the bronchial lumen. By
virtue oftheir location and their possession ofspecific receptors for IgE and complement fragments, these
cells are sentinel cells in host defense. The preformed granular mediators and newly generated lipid
mediators liberated upon activation of mast cells by a variety of secretagogues supply potent vasoactive-
spasmogenic mediators, chemotactic factors, active enzymes, and proteoglycans to the local environment.
Thesefactors actingtogetherinduceanimmediateresponsemanifestasedema, smoothmuscleconstriction,
mucus production, and cough. Later these mediators and those provided from plasma and leukocytes
generate atissue infiltrate ofinflammatory cells and more prolongedvasoactive-bronchospastic responses.
Acute and prolonged responses may be homeostatic and provide for defense ofthe host, but ifexcessive in
degree or duration may provide a chronic inflammatory substrate upon which such disorders as asthma
and pulmonary fibrosis may ensue.
Introduction
The mast cell was identified in 1877 by Ehrlich as a
cell capable of binding basic dyes and of staining
metachromatically (1). Evidence accumulated in recent
years suggests the mast cell has the capacity to
profoundly affect the microenvironment in response to
its interaction with a wide variety of potentially toxic
materials. Although the precise role ofthis cell remains
an issue of intense interest, the knowledge of the
functional capabilities and constituents ofthe mast cell
provide the rationale forassigningit arole inpulmonary
defense and pathobiology.
Location, DevelopmentandStructure
of Mast Cells
Mast cells are found in lung tissue in concentrations
of 1-10 x 106 cells/g. (2). They are prominent in loose
and dense connective tissues (3) such as the pleura,
peribronchial regions and alveolar septa adjacent to
nerves and blood vessels, particularly small arterioles
and venules, and in upper and lowerrespiratory epithe-
lium (4) and free in the bronchial lumen (5,6). Increased
numbers ofmast cells have been identified in humans in
conditions ofexcessivepulmonarybloodflowandchronic
left ventricular decompensation (7), and in association
with pulmonary fibrosis (8), whereas in chronic hypoxic
states proliferation ofmast cells has been noted in rats
(9).
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Although mast cells are prominent in bone marrow
where theirnumbercorrelates withthat oflymphocytes
(10) their origin is from pleuripotential stem cells. Mast
cells develop in long-term tissue cultures of lymphoid
cells from thymus, spleen or lymph nodes on fibroblast
feeder layers (11,12). In addition, monolayers of rat
thymus, rat embryo or mesenchymal cells from rat
retina may develop mast cells in the absence of
fibroblasts, suggesting that mast cells develop from a
widespread primitive mesenchymal precursor. Regula-
tion ofmast cell proliferation may thus be regulated by
both neuroectodermal factors (13) and T-lymphocytes
(12). In rodents, mast cells divide and increase in
number throughout fetal and neonatal life (14), but
mitoses are rare later (15). It is uncertain how mast
cells come to be situated in the lung at various sites at
which they can be found; presumably, precursor mesen-
chymalmastoblasts differentiatelocally, however, migra-
tion of mast cells through tissue may occur in some
disorders (16). Individual mast cells are long-lived,
persisting for up to one-third of the total life span in
rats, and the size of the mast cell increases as the
animal ages (17).
Mast cells are large, measuring 10 to 15 ,um in
diameter with the usual cellular organelles including a
nucleus, one or two nucleoli, mitochondria, Golgi
apparatus, ribosomes and endoplasmic reticulum. In
addition, these cells possess a ruffled membrane (18,19)
and 50 to 200 individually membrane bound secretory
granules (0.5-0.7 ,um diameter) towhich, inthehuman,
areapposednumerousintermediate-sizedfilaments(20).
The secretorygranules ofthe human mast cellpossess a
definite subgranular architecture dominated by repeat-
ing subunits ofelectron density 750 and 1500 mu apartS. I. WASSERMAN
which give the granules a scroll or whorl-like appear-
ance (20-22). Microtubules have not been identified in
human mast cells.
Activation of Mast Cells
A variety ofagents have been demonstrated to cause
mast cells to release theirgranules, as defined histologi-
cally or by the measurement in tissue or fluid of mast
cell constituents. Mast cell degranulation in cells of
tissues has been induced by IgE-dependent mecha-
nisms and, in addition, by divalent cation ionophores
(23,24), highly charged amines (25), ATP (26), ana-
phylatoxins C3a and C5a (27), enzymes such as chy-
motrypsinandphospholipases (28), divalentcations (29),
cationicpeptides and enzymes frominflammatory leuko-
cytes (30), drugs such as morphine and curare (31),
endotoxin (32), fragments of ACTH (33), synthetic
peptide chemotactic factors, complex carbohydrates
(34), and environmental pollutants such as NO2 (35).
Activation of mast cells is thought to occur in a
non-cytolytic secretory process induced by binding of
activating substances to specific receptors on the mast
cell membrane. This process has been most extensively
studied in the rat mast cell which can be purified to
homogeneity. Inthis cell, bridgingoftwocell bound IgE
molecules by specific antigen or by antibody to either
IgE or to the cell membrane receptor for IgE is
sufficient to induce cell activation (36). Similiar mecha-
nisms dependent upon IgE have been demonstrated to
activate dispersed human lung cells in suspension (37)
or enriched populations of human lung mast cells (2,
20). The action ofother moieties such as C3a, C5a, and
chemotactic peptides are also presumed to be conse-
quent to their ability to bind to and alter specific
membrane receptors. Following binding there is an
opening of membrane channels for Ca2+ions, and an
influx of this ion occurs, perhaps in exchange for
monovalent cations. Inhibition of calcium flux or
removal ofthis ion from the medium prevents degranu-
lation. In association with calcium fluxes, there is
intracellular granule swelling and dissolution accom-
panied by intermediate filament organization at the
granule periphery (20), granule to granule membrane
fusion, fusion of granular to plasma membranes (38),
and eventually the development of membrane discon-
tinuities exposing the partially solubilized granules to
cation exchange (39).
BiochemicalRegulationofMastCell
Activation
The biochemsitry of mast cell activation has been
derived primarily from studies with rat mast cells or
from mast cell rich tissues in the human including lung
fragments (40) or cells (37), partially purified human
lung mast cells (2), nasal polyps (41), and skin (42).
While mixed cell sources can provide insight into the
overall effects of mast cell activation the precise role of
the mast cell requires study of nearly pure cell
populations. As this has only been achieved to date
utilizing rat mast cells the insights gained from this
model will be presented and, where relevant, the
findings in human systems described.
The regulation of mast cell activation was shown to
involve the nucleotide cyclic 3'5'-adenosine monophos-
phate (cAMP) more than 10 years ago (40). A series of
investigations followed which demonstrated that agents
which elevated levels of cAMP (PGE2, B-adrenergic
agonists, cholrea toxin, dibutyl cAMP) or prevented its
degredation (methylxanthine) inhibited mediator re-
lease in lung cells of tissues; whereas agents which
lowered the concentration of the nucleotide (PGF2a,
alpha-adrenergic agonists) augumented mediator re-
lease (43). However, subsequent studies employing
purified rat mast cells provided data which cast the role
ofcAMP into some doubt. Thus some mast cell secreta-
gogues increased, while other decreased cAMP levels
(44). In addition, theophylline inhibited mediator re-
lease even at concentrations insufficient to prevent
cAMP degradation, while PGD2 and 3-isobutyl-1-
methylxanthine (IBMX) enhanced mast cell cAMP
accumulation, and the later agent even augumented
mediator release (45). These contradictory findings
have been partially clarified by the finding that activa-
tion ofrat mast cells leads to two sequential elevations
in cAMP, the first occurring 15-30 sec after stimulation,
and the second 90-220 sec later. The second peak can be
inhibited by indomethacin and is secondary to mast cell
released mediators, whereas the first is intimately
associated with the secretory process (46). The finding
that adenosine enhanced histamine release from rat
mast cells led to the finding that analogs of this
nucleotide were capable of altering the early peak in
cAMP Thus purine modified analogs of adenosine
enhance immunologically induced early increases in cell
cAMP and enhance histamine release, whereas ribose
modified analogs inhibited both phenomena (47).
Consequent to cAMP elevation is the utilization of a
cAMP dependent protein kinase (48), phosphorylation
ofintracellular proteins (49) and granule release. Taken
together these data suggest that mast cell activation
and mediator release is dependent upon activation of
adenylate cyclase and increase in cell cAMP Agents
which act to augment cyclic AMP and also inhibit
mediator release presumably do so by affecting concen-
trations ofkey intermediates (such as the cAMP depen-
dent protein kinase) in a manner which prevents their
effective utilization during cell activation by secre-
tagogues.
A parallel event in mast cell activation is that oflipid
methylation. Within seconds ofactivation, three methyl
groupsmaybetransferred tophosphatidylethanolamine
to generate phosphatidylcholine. The initial methyla-
tion occurs at the inner aspect ofthe plasmamembrane,
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whereas the latter two are at the outer membrane
surface. Agents capable of inhibiting methylation in-
hibitmediatorrelease and alsoblockCa2+ uptake bythe
activated cells (50). Lipid methylation is associated with
increases in membrane fluidity and perhaps in regulat-
ing activity of a putative calcium channel (51). The
calcium ionophore A23187 does not require a calcium
channel as it directly induces Ca2+ influx, and this
secretagogue does not augment lipid methylation (52).
It is ofgreat interest that inhibitors oflipid methylation
prevent mediator release but do not alter early cAMP
increases, and conversely inhibitors of early cAMP
accumulation prevent mediator release, but not lipid
methylation (53).
Other lipid alterations also occur consequent to mast
cell activation. Diacylglycerol, a potent fusogen, is
generated following the action of a putative phos-
pholipase C upon membrane phospholipids (54) and
there are rapid increases in turnover of phosphatidic
acid, arachidonic acid, phosphatidyl inositol and phos-
phatidyl ethanolamine. The liberation of arachidonic
acid and its metabolism appears critical to degranu-
lation. Indomethacin, whichinhibits the cyclooxygenase
pathway of arachidonic acid metabolism may enhance
mediator release, whereas inhibitors of both lipoxy-
genase and cyclooxygenase dependent pathways of
arachidonate metabolism inhibit mediator release.
Hydroperoxides of various lipids including those of
arachidonate enhance mast cell mediator release (55).
Arachidonic acid may be liberated from mast cell lipids
by phospholipase A2 active on intact phospholipids or
by diacylglycerol lipase action on diacylglycerol.
Other steps in cell activation have been postulated.
The role of microtubules, microfilaments, and other
cytoskeletal elements have been proposed. Direct evi-
dence for the existence of intermediate filaments have
been obtained in human lung mast cells (20), and these
structures become closely associated with the cell and
granule membrane during activation. Microfilament
participation has been suggested by the inhibitory
effect on mediator release of cytochalasin B, but the
concentrations required to demonstrate this effect are
far in excess ofthose needed to affect microfilaments in
other tissues (56). The participation ofa serine esterase
in cell activation has been postulated (57) and ques-
tioned (58).
Mast Cell Mediators
The activation of mast cells leads to the release of
preformed granule-associated molecules and to the
generation and release ofother, unstored, materials. In
toto, these complex, biologically active molecules
termed mediators may best be classified as to their
biological effects. Thus, mast cell related materials with
vasoactive, smooth muscle reactive properties (Table 1),
with chemotactic potential (Table 2) as well as active
enzymes and structural proteoglycans (Table 3) have
been recognized.
MediatorsActingonSmoothMuscle
and Vasculature
Histamine
The first mast cell mediator identified, histamine
(P-imidazolylethylamine), is formed by the action of
histadine decarboxylase upon the amino acid histidine.
The amine, in amounts of 10 to 30 pLg/106 cells in the rat
(59) and 1 to 5.5 pug/1O6 mast cells in the human (2), is
stored preformed in the granules where it is bound to
proteoglyean, or protein carboxyl residues. Histamine
content of human lung approximates 10 to 20 ,ug/g.
Catabolism ofhistamine proceeds via two pathways (60)
both active in lung (61). The majority (46-55%) is
transformed to 3-methylhistamine by the action of
imidazole-N-methyl transferase. Aremaining25-34 per-
cent of histamine is oxidized to imidazole acetic acid,
and its riboside, by the action of diamine oxidase. The
remainder, 2 to 3%, is excreted unchanged in the urine.
Histamine induces contraction ofairway smooth mus-
cle (62), resulting in increased resistence and diminished
compliance (63-65). The amine also causes increased
mucous secretion, pulmonaryvasoconstriction andinduces
bronchial venularleakage resultingin pulmonary edema
(66). Transient increases in heart rate and cardiac
output, as well as slowed A-V conduction, follow its
injection (67,68).
Histamine exerts its effects on lung by interacting
with two cell membrane-associated receptors termed
Hi and H2 (69). The interaction ofhistamine with those
receptors has been assessed employing analogs with
selective Hi (2-methylhistamine) or H2 (4-methylhista-
mine) action, or by the use of specific H1 or H2
inhibitors. H1 blocking agents comprise the so-called
classical antihistamines whereasthe H2inhibitors include
only the closely related metiamide, burimimide and
cimetidine. Both Hi and H2 receptors are present in
human lung (70), and analysis of the role of each in
the effect of histamine indicates that pulmonary vaso-
constriction, bronchial smooth muscle contraction, and
systemic vasodepression are Hi effects (67), whereas
H2 activation is associated with pulmonary vaso-
depression, augmentation in cardiac output and heart
rate (67), and inhibition of anaphylaxis (71). The latter
effect is thought secondary to histamine induced inhibi-
tion of mediator release secondary to cAMP elevation
(72,73). Histamine also mediates the wheal and flare
response in skin due to its ability to cause venular
disconnections (74), and causes pain and itch (75).
Cutaneous edema resists Hi and H2 blockage and may
reflect histamine induced PGE2a generation (76). In
addition, histamine can modify the action ofa variety of
inflammatory cells. Thus by H2 induced accumulations
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Table 1. Vasoactive mediators.
Structural
Mediator characteristics Function Inhibition Inactivation
Histamine ,B-Imidazolyl- Contraction of smooth muscle H1 and H2 Histamine
(mast cells) ethylamine, Increase of vascular permeability antihistamines (diamine oxidase)
MW 111 Stimulation of suppressor T-lymphocytes (H2) or
Generation of prostaglandins Histamine
Enhancement of(HI) or inhibition (H2) of chemotaxis N-methyl transferase
Elevation of cAMP (H2) and cGMP (H1)
Increase mucus production
SRS-A Leukotrienes Contraction of smooth muscle FPL-55712 Arylsulfatases A and B
(Neutrophils C=5 (S)-OH-6 (R)- Increased vascular permeability Peroxidases
monocytes S-glutathionyl-7,9- Synergistic with histamine Lipoxygenase
?mast cells) trans-11,14-cis- Generation of prostaglandins Peroxides
eicosatetraenoic Vasodepressor
acid Cutaneous
Vasoconstriction (C)
D=5-(S)-OH-6(R)-S- Vasodilatation (D,E)
cysteinylglycyl-
7,9-trans-11,14-cis-
eicosatetraenoic acid
E =5(S)-OH-6(R)-S-
cysteinylglycyl-7,9-
trans, 11,14-cis-
eicosatetraenoic acid
Serotonin 5-OH-tryptamine, Contraction of some smooth muscle Hydroxyzine Monoamine oxidase
(platelets) MW 182 Increased vascular permeability Cyproheptadine
lysergic acid
PAF 1-O-alkyl-2- Release of platelet amines Unknown Phospholipases
(neutrophils acetyl-sn-glyceryl- Platelet aggregation
monocytes 3-phosphorylcholine Sequestration of platelets
?mast cells) Vasodepression
Bronchospasm
Increased vasopermeability
Prostaglandins C-20 fatty acids Contraction of smooth muscle Synthesis blocked Specific
D2 (mast cells) Vasodepressor by nonsteroidal dehydrogenases
Elevation of cAMP anti-inflammatory
agents
E2
"i Lower cAMP contract smooth muscle
I2 Elevate cAMP, inhibit platelet aggregation, contract
smooth muscle
Thromboxane A2 Contract smooth muscle, stimulate platelet
Many aggregation
Endoperoxides" Contract smooth muscle
(G2, H2)
of cAMP or prostaglandin F 2a the amine inhibits
eosinophil, neutrophil and basophil leukocyte chemo-
taxis (77,78) and activates suppressor lymphocytes
(79), while (perhaps by its ability to augment cGMP
levels) Hi actions enhance cell motility (80). Histamine
also inhibits lymphocyte mediated cytotoxic responses-
(81) and activates suppressor cells.
Platelet Activating Factor (PAF)
Platelet activating factor (PAF) was first described as
an activity which was generated during anaphylaxis in
the rabbit (82), capable of aggregating rabbit platelets
and releasing their stored amines. PAF has been
identified structurally as 1-alkyl-2-acetyl-sn-glyceryl-
3-phosphorylcholine (21). This mediator is generated by
rabbit basophils after IgE-dependent activation but, in
the human, neutrophilic polymorphonuclear leukocytes
appear to be the source (83). In addition, mononuclear
leukocytes (84), kidney, and spleen (85) can generate
this principle. Direct evidence for PAF generation by
mast cells or during anaphylactic reactions in human
tissue is lacking. In human skin, synthetic PAF has
been demonstrated to cause a wheal-and-flare reaction
when concentrations as low as 10-"M are injected (86).
Inanimals, PAF causeshypotension, pulmonarymechan-
ical alterations (87), is acardiac depressant, and induces
the aggregation and sequestration ofplatelets into lung
and skin, as well as causing circulating neutropenia and
basopenia (88,89). In vitro destruction of PAF can be
mediated by a specific acetyl hydrolase (90), and by
phospholipases C and D (91).
Serotonin (5-HT)
In the human, serotonin is synthesized by sequential
hydroxylation and decarboxylation of the amino acid
trytophan (92), and is then degraded in plasma or tissue
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Table 2. Chemotactic mediators.
Structural
Mediator characteristics Function Inhibition Inactivation
ECF-A (mast cell) Val/Ala-Gly-Ser-Glu Chemotactic attraction and deactivation of Gly-Ser-Glu Amino-peptidase
MW 360-390 eosinophils and neutrophils Val-Gly-Ser Carboxy-peptidase A
ECF-oligopeptides Peptides, Chemotactic attraction and deactivation of Unknown Unknown
(mast cell) MW 1300-2500 eosinophils
Chemotactic attraction of eosinophils and mono
nuclear leukocyte deactivation of eosinophils
NCF (?mast cell) Neutral protein, Chemotactic attraction of deactivation of Unknown Unknown
MW > 750,000 neutrophils
Lipid chemotactic HHT (C17 fatty acid) Chemotactic attraction of neutrophils and ETYA (HHT, Specific
factors (unknown) HETE (C20 fatty acid) eosinophils HETE, and dehydrogenases
Leukotriene B Chemokinesis of neutrophils leukotriene B)
Oxidized arachidonic Deactivation of neutrophils Nonsteroidal anti-
acid inflammatory
agents (HHT)
Histamine 3-Imidazolyl- H1 chemotactic and chemokinetic activation of H1 and H2 Histaminase (diamine
(mast cells) ethylamine, eosinophils antihistamines oxidase) or
MW = 111 H2 chemotactic and chemokinetic inhibition of Histamine
neutrophils and eosinophils N-methyltransferase
Table 3. Mast cell enzymes and proteoglycans.
Structural
Mediator characteristics Function Inhibition Inactivation
Proteoglycans
Heparin (preformed) Proteoglyean Anticoagulation Protamine Heparinase
MW 60,000 Antithrombin III interaction
Inhibition of complement activation
Liberation of lipoprotein lipase and phospholipase
Enzymes
Arylsulfatase Proteins, Hydrolysis of SRS-A and various sulfate esters P04, S04 product, Unknown
(preformed) MW= 100,000 (A) substrate
60,000 (B)
N-Acetyl-,B-D- Proteins, Cleavage of glucosamine Product Unknown
glucosaminidase MW= 158,000
Tryptase Protein, Proteolysis with tryptic specificity Tryspin inhibitors Unknown
(kallikrein) MW -400,000 Cleavage of kinin from kininogen
anaphylaxis Cleavage of Hageman factor
3-Glucuronidase Protein, Cleavage of glucuronide conjugates Product Unknown
MW -300,000
Superoxide Protein Cleavage of 02- Unknown Unknown
dismutase
Myeloperoxidase Protein Cleavage of H202 Unknown Unknown
bymonoamine oxidase (93). Thehuman platelet, but not
the mast cell, takes up and stores this amine inits dense
granules from which it may be liberated by the action of
PAF and other secretagogues. The blood platelet con-
tent ofserotonin is 0.1 to 0.2 ng/mL (94). Serotonin is a
vasoconstrictor but is a relatively ineffective agonist
upon human pulmonary vasculature orbronchial smooth
muscle.
Oxidative Products of Arachidonic Acid
Arachidonic acid, a C20 fatty acid with four double
bonds, is a prevalent fatty acid in mammalian mem-
brane phospholipids. It is liberated from intact phos-
pholipids by the action of phospholipase A2 or from
diacylglycerol by the action ofdiacylglycerol lipase. The
phospholipase A2 mediated liberation of arachidonic
acid from phospholipids is inhibited by glucocorticoids
(95), possibly due to steroid induced synthesis of
macrocortin (96), a phospholipase A2 inhibitor. Once
liberated, the metabolic fate of arachidonic acid is
extremely variable, with many potential end products
known. However, each cellgenerates only afew selected
metabolites. Two major enzymes, lipoxygenase and
cyclooxygenase, regulate the fate of arachidonic acid.
Cyclooxygenase. Theactionofcyclooxygenase, an
enzyme inhibitable by aspirin and other nonsteroidal
anti-inflammatory drugs, generates the cyclic endoper-
oxides, PPG2 and PGH2 (97). These, in turn, are
substrates for other enzymes which generate pros-
tacycline (PGI2), PGE2, PGF2a, PGD2, HHT, and
thromboxane A2 (98). Many of the cyclooxygenase
products have potent effects on smooth muscle and
vasculature. The cyclicendoperoxides, PGG2and PGH2,
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and thromboxane A2 are vasoconstrictors (99), whereas
PGI2 is a potent vasodilator (100). PGI2 is the major
prostaglandin product in blood vessel walls, and may be
relavent to the development of edema and erythema
directly and also by its ability to potentiate the edema
and erythemainduced byotherinflammatorymediators,
such as bradykinin (101). PGE2 and PGD2 are potent
molecules capable of inducing edema, erythema, vaso-
depression, vasodilatation, and smooth muscle contrac-
tion (102), however PGE2 is a bronchodilator (102).
PGF2a, a potent bronchoconstrictor, is thought also to
augment vasopermeability. The isolated cell of the
human and rat generates only PGD2 upon immunologic
stimulation (103), and patients with mastocytosis have
been reported to excrete large quantities of a PGD2
metabolite in their urine (104).
Lipoxygenase. Theinitialproductoflipoxygenase
action on arachidonic acid is hydroperoxy eicosatetra-
enoic acid. This is then further metabolized to a series
of monohydroxy eisosatetraenoic acids (HETEs) or to
the leukotrienes (105). Leukotriene C is a glutathionyl
(Gys-Gly-Glu) derivative of leukotriene A, whereas D
lacks the terminal glutamine residue and E the terminal
glycylglutamyl residues (106,107). All are bronchocon-
strictors in nanogram amounts, and C and D are
systemic vasodepressors (106). Leukotriene C is a
vasoconstrictor, whereas D is a vasodilator. The sequen-
tial conversion of the leukotrienes from C to D to E is
likely, with leukotriene D the most potent ofthe three is
most assay systems. These molecules comprise what
has heretofore been termed slow-reacting substances of
anaphylaxis (SRS-A).
Rat mast cells have been demonstrated to generate
leukotrienes uponcalciumionophore-induced activation,
and release ofthese molecules induced by immunologic
secretagogues has been demonstrated in the guinea pig
and human lung mast cells. As IgE activation in lung
tissue (40) and cells (37) is associated with SRS-A
production, but SRS-A generation may decrease as
mast cells are purified (2), it is possible that other cell
types also generate these products for export. Inhibi-
tors of lipoxygenase activity (such as ETYA) inhibit
histamine release, and it is conceivable that the major
site of action of mast cell lipoxygenase products is
within the cell.
Bradykinin
A nonpeptide cleaved from kininogen by kallikrein,
bradykinin has potent activity on smooth muscle and
alters vascular permeability. Direct evidence for its
generation in human disease, particularly mast cell-
dependent processes, however, is lacking. Bradykinin is
a vasoconstrictor but in humans can cause hypotension
due to peripheral arterial dilatation. In addition, it
increases vascular permeability. Bradykinin is rapidly
inactivated and its half-life in serum is less than 60 sec.
Although the presence of bradykinin in tissue extracts
in disease has been reported, the rapid turnover ofthis
molecule and the ease ofits generation following tissue
extractionmake interpretation ofthesereports difficult.
Chemotactic Mediators
Eosinophil Chemotactic Factor of Anaphy-
laxis (ECF-A)
ECF-A is released immunologically from mast cell-
rich tissues and rat and human mast cells where it is
stored preformed in the granules (108). Two tetrapep-
tides of the sequence Val or Ala-Gly-Ser-Glu have been
extracted from whole human lung and demonstrated to
possess many ofthe properties ofECF-A (109). ECF-A,
as a less well characterized eosinophilotactic activity
from other sources, is defined as a chemotactic activity
of 300 to 700 daltons, susceptible to proteases, and
which is highly acidic (110). ECF-A attracts eosinophils
into skin in vivo (111) as well as through micropore
chambers in vitro and is a potent chemotactic deactiva-
tor (108). ECF-A increases the number of eosinophil
membrane receptors for C3b and C4 (112).
ECF-Oligopeptides
Molecules of 1000-3000 daltons with chemotactic
activity for eosinophils have been identified preformed
in rat mast cells and are released from them following
immunologic activation (113). These presumptive pep-
tides are heterogeneous. Molecules ofsimiliarmolecular
weight and activity have been extracted from whole
human lung (114).
High Molecular Weight Neutrophil
Chemotactic Factor (HMW-NCF)
A factor of high molecular weight chemotactic for
neutrophils is extracted from human lung tissue (114)
and rat mast cells (115) and is present in serum of
patients after experimental induction ofIgE-dependent
bronchospasm (116) or cold urticaria (117). The mole-
cule from the latter source has a mass in excess of
600,000 daltons, a neutral isoelectric point, and in
addition to chemotactic activation, it is able to deacti-
vate neutrophils.
Histamine
Histamine is capable of modulating random and
directed migration of both neutrophils and eosinophils.
At low doses, histamine augments these responses by
an Hi action, whereas at higher concentrations an
inhibitory H2 effect predominates (77, 80). Histamine is
capable of augmenting eosinophil C3b receptors (112).
Arachidonic Acid Metabolites
Although none of the products generated from
arachidonic acid by mast cells has been shown to be
chemotactic, a wide variety ofarachidonate metabolites
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are potent chemotactic factors. A cyclooxygenase prod-
uct HHT (118) as well as some lipoxygenase products,
including the family of monohydroxyeicostaetranoic
acids (HETEs) (119), and leukotriene B4 (120) are
chemotactic for neutrophils, and 5-,8- and 11-HETE
possess activity for eosinophils.
Other Chemotactic Factors
Uncharacterized lipids (121) and PAF have also been
shown chemotactic for neutrophils.
Active Enzymes
Proteases
Thegranules oftheratmastcellcontain asingle-chain
active chymotryptic protease of molecular weight
25,29,000 (122). In human mast cells, no chymotryptic
enzyme is present, and instead a tryptic protease
termed kallikrein has been identified. This enzyme, or
family of enzymes, has been found in populations of
human lung mast cells (123), and in anaphylactic diffu-
sates of human lung (124). Little is known of the
specificity, inhibitor profile, or total cellular content of
mast cell tryptic proteases. The activation ofHageman
factor and cleavage of bradykinin from kinonogen may
be expected consequence of release of this enzyme.
Other Lysosomal Proteases
Human lung mast cells have been demonstrated to
contain and release arylsulfatase, ,B-glucuronidase, and
hexosaminidase after immunologic activation (123),
while rat mast cells possess these enzymes, an amino
peptidase and other acid hydrolases (such as 1-D-
galactosidase) with specificity forcarbohydrate moieties
(125,126), peroxidase (127), superoxide dimutase and
superoxide generating enzymes (128).
Structural Proteoglycans
Rat and human mast cell granules contain proteo-
glycan heparin of high molecular weight (129,130) rich
in N and 0 sulfated sugars. Heparin release from rat
mast cells have been demonstrated but lags behind that
of histamine due to its relative insolubility (126).
Heparin can inhibit classical and alternative pathways
to complement activation (131,132), and activates many
enzymes due to its ability to interact with antithrombin
III (133). In addition, heparin can liberate lipoprotein
lipase and phospholipase (134), and induce lymphocyto-
sis (135).
Role of MastCells and Mast Cell
Mediators in Disease
The most compelling evidence for the role of mast
cells and mediators derives from experiments in skin in
which mast cell activation was induced by specific
antigen. Theparticipation ofotherimmunologic classes,
and thus other potential inflammatory pathways, was
excluded in these experiments by use of purified
antigen-specific IgE and passively sensitized non-
allergic hosts (136). Injection ofspecific antigen to such
passively sensizited hosts induced mast cell activation
and a clinical response described as a dual phase
reaction (136,137). The initial phase is characterized
clinically by a wheal-and-flare beginning in minutes,
persisting several hours, which is histologically repre-
sented by mast cell degranulation, dermal edema, and
endothelial cell activation. After 4 to 12 hr a large
inflammatory, indurated lesion develops which persists
for 18to24 hrand which is represented histologicallyby
edema, infiltration of the dermis by neutrophils,
eosinophils, basophils, lymphocytes, and mononuclear
leukocytes, and in some instances hemorrhage, blood
vessel wall damage, and fibrin deposition of sufficient
severity to warrantthe diagnosis ofvasculitis (136). The
mediators responsible for these pathophysiologic mani-
festations have not yet been identified; however, they
can be surmised by their known effects as isolated
mediators. Thus, the initial phase is most likely due to
the concerted action of the vasoactive mediators. The
effect of these mediators to induce edema and alter
blood flow may also permit the localization in tissue of
immunoglobulin, complement, and the proteins of the
clotting, fibrinolytic, and kinin generating pathways.
These proteins acting together with the chemotactic
factors may well be responsible for the later inflam-
matory phase seen in the skin. Vasculitis may well
reflect the hydrolytic action of infiltrating leukocyte
lysosomal enzymes, but may also be due to direct action
of the mast cell acid hydrolases.
No studies of such elegance, employing lung tissues,
have been reported. However, early and late broncho-
spastic responses to antigen have been recorded in
humans. As both pulmonary responses maybe inhibited
by the mast cell active agent disodium cromoglyeate
(138) while only the latteris inhibited by corticosteroids
it is reasonable to suggest similiar mast cell dependent
inflammatory pathophysiologic alterations can occur in
lung.
Mast Cells and Mediators
in Pulmonary Responses
to Toxic Agents
There is little direct evidence implicating or ruling
out the participation of mast cells and/or mediators in
the response ofthe lung to toxic materials, save for the
extensivebodyofknowledge concerningIgE-dependent
responses to airborne allergens. More narrowly defined
toxic exposure mayhoweverinvolvethe mast cell and its
vasoactive, smooth muscle reactive, chemotactic and
enzymatic mediators. The presence ofmast cells free in
the bronchial lumen and in the pulmonary epithelium
(see above) serve to place the mast cell at the host-
265266 S. I. WASSERMAN
environment interface. Whether the role of the mast
cell is harmful or beneficial may reflect the intensity,
duration or character ofthe stimulus, the presence and
nature of underlying systemic or pulmonary disease
(i.e., immotile cilia syndromes, cystic fibrosis, a1-
antitrypsin deficiency, etc.), individual responsiveness
toindividualmediators aswellas differencesindegrada-
tion ofmediators and/or recruitment ofalternate pro- or
anti-inflammatory systems.
It is known that NO2 exposure (1 ppm for 2 hr or 0.5
ppm for 4 hr) induces mast cell destruction in rats (35).
Oxygen toxicity is exacerbated by histamine and de-
creased by antihistamine (139), a fact which may reflect
direct mast cell participation in 02 toxicity. In addition,
lipid peroxides, known to be generated during exposure
to high partial pressures of 02, may enhance mast cell
mediator release. Studies of the histopathologic alter-
ations in lung consequent to 02 toxicity fail to discuss
mast cells. This may reflect the relative paucity of
epithelial mast cells but may also indicate that mast
cells are degranulated, and this no longer visible,
following induction of 02 toxicity. Rat mast cells and
human lung tissue also can generate oxygen radicals
during IgE-dependent mast cell activation, while the
mast cell also possesses superoxide dismutase and
peroxidase, enzymes thought capable of blunting oxy-
gen induced toxicity.
It is also possible that the mast cell, present at the
host-environment interface may provide a "detoxifica-
tion" role. Such a role is suggested by the long life of
this cell, its highly charged granule core, its content of
active enzymes, its known capacity to ingest particulate
materials by phagocytosis or pinocytosis and the pro-
longed presence of indigestible materials in mast cell
granules (i.e., ThO2) (17,140). Moreover, the ability of
the mast cell mediators to alter local blood flow, to alter
pulmonary airflow by affecting airway diameter and
mechanics, to induce mucous production, and to stimu-
late irritant receptors could provide a mechanism for
preventing and/or removing inhaled toxic materials
before they can impact upon the lung itself. The
recruitment of plasma systems and leukocytes also
potentially benefit clearance and/or localization oftoxic
inputs. When toxic exposures are excessive then mast
cell mediated protection may be overcome, or excessive
mast cell activation may provide edematous, exudative
and inflammatory alterations harmful to the host.
Dr. Wasserman is the recipient of an Allergic Disease Academic
Award No. 00431.
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